Sector pending / Biological Products, Except Diagnostic SubstancesUpdated 2026-05-10 22:07 UTC

FRA/C17 stock hub

FRA/C17 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

FRA/C17is not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1.1B

Frankfurt Stock Exchange

Market data

Price

Recent price action with selectable time range.

FRA/C17FRA/C17

—

Loading chart…

In the news

Latest news · FRA/C17

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-30.5

P25 n/aP50 n/aP75 n/a

ROIC-20.5

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All FRA/C17 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

143

Groups with data

Currency

USD

Showing 143 of 143 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United States
Country code	DE
Employees	37
Employees Change	3%
Employees Change Percent	10.71
Enterprise value	EUR 910.5M
Exchange	Frankfurt Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Biological Products, Except Diagnostic Substances
Last refreshed	2026-05-10
Market cap	EUR 1.1B
Price	EUR 12.28
Price currency	EUR
Sic	2836
Symbol	fra/C17
Website	https://www.corvuspharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-3.45%
EV Earnings	-23.77x
EV/FCF	-29.88x
FCF yield	-2.74%
P/B ratio	5.32x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	EUR -38.3M
Profit Per Employee	EUR -1M
ROA	-19.16
Roa5y	-28.24
ROCE	-19.88
ROE	-30.46
Roe5y	-73.89
ROIC	-20.52

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	1.21%
Cagr1y	325.9%
Cagr3y	127.64%
Cagr5y	39.31%

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	EUR 219.6M
Cash	EUR 205.3M
Current Assets	EUR 203.5M
Current Liabilities	EUR 10.3M
Debt	EUR 723,328
Debt Equity	EUR 0
Debt FCF	EUR -0.02
Equity	EUR 208.7M
Liabilities	EUR 10.9M
Long Term Assets	EUR 16.1M
Long Term Liabilities	EUR 586,307
Net Cash	EUR 204.6M
Net Cash By Market Cap	EUR 18.41
Net Cash Growth	447.81%
Net Debt Equity	EUR -0.98
Tangible Book Value	EUR 208.7M
Tangible Book Value Per Share	EUR 2.48

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	19.81
Net Working Capital	EUR -7.3M
Quick ratio	19.65
Working Capital	EUR 197.6M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-24.98%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	12.8%
1Y total return	325.48%
200-day SMA	9
3Y total return	1,080.29%
50-day SMA	13.07
50-day SMA vs 200-day SMA	50over200
5Y total return	424.57%
All Time High	21.7
All Time High Change	-43.43%
All Time High Date	2026-01-23
All Time Low	0.57
All Time Low Change	2,047.48%
All Time Low Date	2023-03-28
ATR	0.63
Ch YTD	98.3
High	12.28
High52	21.7
High52 Date	2026-01-23
High52ch	-43.43%
Low	12.28
Low52	2.94
Low52 Date	2025-05-23
Low52ch	325.48%
Ma50ch	-6.1%
Price vs 200-day SMA	36.43%
RSI	45.41
RSI Monthly	62.88
RSI Weekly	54.07
Sharpe ratio	1.36x
Sortino ratio	3.59
Total Return	-24.98%
Tr YTD	98.3
Tr1m	-0.65%
Tr1w	-4.03%
Tr3m	-22.01%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR -41.6M

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	71,342,846%
Shares Insiders	3.51%
Shares Institutions	49.42%
Shares Qo Q	8.48%
Shares Yo Y	24.98%
Short Ratio	13.24

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	EUR -36.3M
Average Volume	1.5x
Bv Per Share	2.48
CAPEX	EUR -198,612
Ch10y	12.8
Ch1m	-0.65
Ch1w	-4.03
Ch1y	325.5
Ch3m	-22.01
Ch3y	1,080.3
Ch5y	424.6
Ch6m	89.72
Change	-3.99%
Change From Open	-0.04
Close	12.79
Days Gap	-3.99
Depreciation Amortization	94,971.7
Earnings Date	2026-05-07
EBIT	EUR -41.6M
EBITDA	EUR -41.5M
EPS	EUR -0.48
F Score	2
FCF	EUR -30.5M
FCF EV Yield	-3.35x
Financing CF	196,786,901
Fiscal Year End	December
Founded	2,014
Investing CF	-136,066,361
Is Primary Listing	0
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Ma150	10.5
Ma150ch	16.89%
Ma20	13.11
Ma20ch	-6.38%
Net CF	30,444,832
Next Earnings Date	2026-05-12
Open	12.28
Ppne	875,944.7
Price Date	2026-05-08
Ptbv Ratio	5.32
Relative Volume	20x
Share Based Comp	5,836,062
Tr6m	89.72%
Volume	0

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does FRA/C17 pay a dividend?

Capital-return profile for this ticker.

Performance

FRA/C17 stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns FRA/C17?

Insider, institutional, and short-interest positioning.

Institutional ownership

+49.4%

Share of float held by funds and institutions

Insider ownership

+3.5%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

FRA/C17 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

45.4

Neutral momentum band

Price vs 200-day MA

+36.4%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

1.35

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About FRA/C17

Hub-level FAQ points readers to the deeper analysis pages.

What is the current fra/C17 stock rating?

fra/C17 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full fra/C17 analysis?

The full report lives at /stocks/fra/C17/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for fra/C17?

The latest report frames fra/C17 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the fra/C17 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.